logo
Plus   Neg
Share
Email

Enbridge : MPUC Rules Line 3 Replacement Project' EIS, Certificate Of Need And Route Permit Valid

Enbridge Inc. (ENB,ENB.TO) said that the Minnesota Public Utilities Commission or MPUC voted to deny petitions for reconsideration filed on May 21, 2020 in the Line 3 Replacement Project or L3RP environmental impact statement or EIS, certificate of need or CN and route permit or RP dockets.

"The MPUC's decision to deny the petitions for reconsideration is yet another important step forward for the Line 3 Replacement Project," said Vern Yu, Enbridge Executive Vice-President and President, Liquids Pipelines.

The company noted that L3RP not only meets Minnesota's energy needs, it replaces an aging pipeline with one built to the newest standards and using modern construction techniques.

L3RP is a shovel-ready, US$2.9 billion private investment that will bring 4,200 union construction jobs, millions of dollars in local spending and tax revenues at a time when Northern Minnesota needs it most.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Despite the coronavirus pandemic, retailers are prepared for an early start to the holiday shopping season by offering discounts earlier so that consumers can buy and receive the gifts they want in time, the National Retail Federation or NRF said. The NRF also said it is launching a nationwide consumer education campaign called "New Holiday Traditions". Facebook (FB) has revealed new messaging features for Instagram, which will make it easier for users to stay in touch with others across Facebook's family of apps. The main change is that people using the Messenger app can now reach Instagram users, and vice versa. The users can control where they receive... Regeneron Pharmaceuticals, Inc. announced positive first data from a descriptive analysis of a seamless Phase 1/2/3 trial of its investigational antibody cocktail REGN-COV2 in COVID-19 patients. REGN-COV2 rapidly reduced viral load and associated symptoms in infected COVID-19 patients. The company said it plans rapidly to discuss results with regulatory authorities.
RELATED NEWS
Follow RTT